Form 4: Vita Coco Executive Chairman Sells Shares
Insider Transaction Report
Vita Coco Company, Inc. Executive Chairman Michael Kirban reported the sale of 44,898 shares of common stock in late October 2025, executed under a Rule 10b5-1 trading plan.
Summary
- Michael Kirban, Executive Chairman and Director of Vita Coco Company, Inc. (COCO), reported transactions involving the sale of common stock.
- On October 29, 2025, 30,000 shares of common stock were sold at a price of $45.701 per share.
- On October 30, 2025, an additional 14,898 shares of common stock were sold at a weighted average price of $44.211 per share, with prices ranging from $44.00 to $45.00.
- These sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
- Following these transactions, Michael Kirban beneficially owns 1,484,151 shares indirectly through the Michael Kirban 2010 Trust.
- Additionally, Michael Kirban directly owns 127,629 shares of common stock and indirectly owns 615,681 shares through the Michael Kirban Revocable Trust.
- The filing also details various non-qualified stock options held by Mr. Kirban, with exercise prices ranging from $10.178 to $32.78 and expiration dates extending to March 3, 2035. Some options are fully vested, while others vest in annual installments through March 3, 2026.
Sentiment
Score: 4
Explanation: The sentiment is neutral to slightly negative. While insider selling can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan mitigates concerns that the sale is based on new, undisclosed negative information. It's a pre-planned transaction.
Positives
- The sales were executed under a Rule 10b5-1 trading plan, indicating pre-planned transactions rather than an immediate reaction to new information, which can reduce concerns about insider selling.
Negatives
- The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, could be perceived negatively by some investors as it reduces the executive's direct equity stake.
Future Outlook
This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's equity management strategy.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The reported sales were made pursuant to a Rule 10b5-1 trading plan, which allows insiders to set up a pre-arranged plan to buy or sell company stock at a future date. | N/A | This demonstrates adherence to SEC regulations designed to prevent insider trading and provides transparency regarding executive stock transactions. |
Related Party Transactions
- Shares are held indirectly by the Michael Kirban 2010 Trust and the Michael Kirban Revocable Trust, which are related parties to Michael Kirban.
Stakeholder Impact
- Shareholders may observe the reduction in direct equity holdings by a key executive, which could influence their perception of management's confidence, although the 10b5-1 plan context is important.
Key Dates
| Date | Description |
|---|---|
| 12/16/2029 | Expiration date for a non-qualified stock option with an exercise price of $10.178. |
| 01/11/2031 | Expiration date for a non-qualified stock option with an exercise price of $10.178. |
| 10/21/2031 | Expiration date for a non-qualified stock option with an exercise price of $15.00. |
| 03/10/2033 | Expiration date for a non-qualified stock option with an exercise price of $16.91. |
| 03/04/2034 | Expiration date for a non-qualified stock option with an exercise price of $26.18. |
| 03/03/2035 | Expiration date for a non-qualified stock option with an exercise price of $32.78. |
| 10/29/2025 | Date of sale for 30,000 shares of common stock. |
| 10/30/2025 | Date of sale for 14,898 shares of common stock. |
| 10/31/2025 | Date the Form 4 filing was signed. |
Recommendation
holdThis Form 4 filing reports routine insider sales executed under a pre-arranged 10b5-1 trading plan. Such transactions are typically not indicative of a fundamental shift in the company's prospects and are often part of an executive's personal financial planning. Without additional information on the company's performance or strategic direction, a 'hold' recommendation is appropriate, as this filing alone does not provide sufficient grounds for a strong buy or sell decision.
Keywords
Vita Coco, COCO, Michael Kirban, Insider Trading, Stock Sale, 10b5-1 Plan, Executive Chairman, Common Stock, Non-Qualified Stock Option
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.